Thrombosis, the clogging of blood vessels, is a major cause of heart attacks and embolism. Scientists have now engineered the first inhibitors of thrombin, a protease promoting thrombosis, that is ...

Argatroban could revive the practice of acute anticoagulation for reducing disability after stroke, based on the EASE trial from China. In patients with acute ischemic stroke and early neurological ...

SPORTIF V, a North American trial, has now reported the same findings. The protocols of SPORTIF III and SPORTIF V were identical, except that SPORTIF III had an open-label design with blinded event ...

DNA-encoded chemical libraries are collections of compounds individually coupled to unique DNA tags serving as amplifiable identification barcodes. By bridging split-and-pool combinatorial synthesis ...

A novel class of antithrombotic medication, the factor XIa inhibitors, has had a rocky start but is powering through phase III trials, which are now underway. MedPage Today sat down to discuss the ...

Various medical circumstances, including heart attacks and extreme cases of COVID-19, necessitate the use of anticoagulants, medicines that prevent blood clots. But the most commonly used, heparin, ...

Researchers have developed a system for designing protein inhibitors with reversible activity. The method is based on a supramolecular drug that results from the interaction of two or more molecules ...

Coadministration of dabigatran etexilate with the antiplatelet drug clopidogrel had no effect on dabigratran's anticoagulant activity as measured by ECT, activated partial thromboplastin time (aPTT), ...

For people with hemophilia, deficiencies in factor VIII (hemophilia A) or factor IX (hemophilia B) lead to insufficient thrombin generation, which can lead to excessive or spontaneous bleeding. 3,7 In ...